The role of EPID in vivo dosimetry in the risk management of stereotactic lung treatments.
Continuous Quality Improvement
On line measurements
Patient Specific Quality Assurance
Portal Dosimetry
Quality Assurance
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
30
09
2022
accepted:
26
03
2023
medline:
6
11
2023
pubmed:
31
5
2023
entrez:
31
5
2023
Statut:
ppublish
Résumé
In this work we report our experience with the use of in vivo dosimetry (IVD) in the risk management of stereotactic lung treatments. A commercial software based on the electronic portal imaging device (EPID) signal was used to reconstruct the actual planning target volume (PTV) dose of stereotactic lung treatments. The study was designed in two phases: i) in the observational phase, the IVD results of 41 consecutive patients were reviewed and out-of-tolerance cases were studied for root cause analysis; ii) in the active phase, the IVD results of 52 patients were analyzed and corrective actions were taken when needed. Moreover, proactive preventions were further introduced to reduce the risk of future failures. The error occurrence rate was analyzed to evaluate the effectiveness of proactive actions. A total of 330 fractions were analyzed. In the first phase, 13 errors were identified. In the active phase, 12 errors were detected, 5 of which needed corrective actions; in 4 patients the actions taken corrected the error. Several preventions and barriers were introduced to reduce the risk of future failures: the planning checklist was updated, the procedure for vacuum pillows was improved, and use of the respiratory compression belt was optimized. A decrease in the failure rate was observed, showing the effectiveness of procedural adjustment. The use of IVD allowed the quality of lung stereotactic body radiation therapy (SBRT) treatments to be improved. Patient-specific and procedural corrective actions were successfully taken as part of risk management, leading to an overall improvement in the dosimetric accuracy.
Sections du résumé
BACKGROUND AND OBJECTIVE
In this work we report our experience with the use of in vivo dosimetry (IVD) in the risk management of stereotactic lung treatments.
METHODS
A commercial software based on the electronic portal imaging device (EPID) signal was used to reconstruct the actual planning target volume (PTV) dose of stereotactic lung treatments. The study was designed in two phases: i) in the observational phase, the IVD results of 41 consecutive patients were reviewed and out-of-tolerance cases were studied for root cause analysis; ii) in the active phase, the IVD results of 52 patients were analyzed and corrective actions were taken when needed. Moreover, proactive preventions were further introduced to reduce the risk of future failures. The error occurrence rate was analyzed to evaluate the effectiveness of proactive actions.
RESULTS
A total of 330 fractions were analyzed. In the first phase, 13 errors were identified. In the active phase, 12 errors were detected, 5 of which needed corrective actions; in 4 patients the actions taken corrected the error. Several preventions and barriers were introduced to reduce the risk of future failures: the planning checklist was updated, the procedure for vacuum pillows was improved, and use of the respiratory compression belt was optimized. A decrease in the failure rate was observed, showing the effectiveness of procedural adjustment.
CONCLUSION
The use of IVD allowed the quality of lung stereotactic body radiation therapy (SBRT) treatments to be improved. Patient-specific and procedural corrective actions were successfully taken as part of risk management, leading to an overall improvement in the dosimetric accuracy.
Identifiants
pubmed: 37256302
doi: 10.1007/s00066-023-02081-x
pii: 10.1007/s00066-023-02081-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
992-999Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA A Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442
doi: 10.3322/caac.21442
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076. https://doi.org/10.1001/jama.2010.261
doi: 10.1001/jama.2010.261
pubmed: 20233825
pmcid: 2907644
Gomez DR, Blumenschein GR Jr., Lee JJ, Hernandez M, Ye R, Camidge DR et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17:1672–1682. https://doi.org/10.1016/S1470-2045(16)30532-0
doi: 10.1016/S1470-2045(16)30532-0
pubmed: 27789196
pmcid: 5143183
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2018) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. https://doi.org/10.1016/S0140-6736(18)32487-5
doi: 10.1016/S0140-6736(18)32487-5
Albert JM, Das P (2013) Quality indicators in radiation oncology. Int J Radiat Oncol Biol Phys 85(4):904–911. https://doi.org/10.1016/j.ijrobp.2012.08.038
doi: 10.1016/j.ijrobp.2012.08.038
pubmed: 23040217
World Health Organization (WHO) (2008) Radiotherapy risk profile
Mancosu P, Nicolini G, Goretti G, De Rose F, Franceschini D, Ferrari C, Reggiori G, Tomatis S, Scorsetti M (2018) Applying lean-six-sigma methodology in radiotherapy: lessons learned by the breast daily repositioning case. Radiother Oncol 127(2):326–331. https://doi.org/10.1016/j.radonc.2018.02.019
doi: 10.1016/j.radonc.2018.02.019
pubmed: 29523411
Fiagan YAC, Bossuyt E, Machiels M, Nevens D, Billiet C, Poortmans P et al (2022) Comparing treatment uncertainty for ultra- vs. standard-hypofractionated breast radiation therapy based on in-vivo dosimetry. Phys Imaging Radiat Oncol 13(22):85–90. https://doi.org/10.1016/j.phro.2022.05.003
doi: 10.1016/j.phro.2022.05.003
Esposito M, Villaggi E, Bresciani S, Cilla S, Falco MD, Garibaldi C et al (2020) Estimating dose delivery accuracy in stereotactic body radiation therapy: a review of in-vivo measurement methods. Radiother Oncol 149:158–167. https://doi.org/10.1016/j.radonc.2020.05.014
doi: 10.1016/j.radonc.2020.05.014
pubmed: 32416282
Mijnheer BJ, González P, Olaciregui-Ruiz I et al (2015) Overview of 3‑year experience with large-scale electronic portal imaging device-based 3‑dimensional transit dosimetry. Pract Radiat Oncol 5(6):e679–e687
doi: 10.1016/j.prro.2015.07.001
pubmed: 26421834
Piermattei A, Greco F, Grusio M et al (2018) A validation study of a dedicated software for an automated in vivo dosimetry control in radiotherapy. Med Biol Eng Comput 56(10):1939–1947. https://doi.org/10.1007/s11517-018-1822-3
doi: 10.1007/s11517-018-1822-3
pubmed: 29682674
Celi S, Costa E, Wessels C et al (2016) EPID based in vivo dosimetry system: clinical experience and results. J Appl Clin Med Phys 17(3):262–276
doi: 10.1120/jacmp.v17i3.6070
pubmed: 27167283
pmcid: 5690938
Nailon WH, Welsh D, McDonald K et al (2019) EPID-based in vivo dosimetry using dosimetry check™: overview and clinical experience in a 5-yr study including breast, lung, prostate, and head and neck cancer patients. J Appl Clin Med Phys 20(1):6–16
doi: 10.1002/acm2.12441
pubmed: 30536528
Bossuyt E, Weytjens R, Nevens D, De Vos S, Verellen D (2020) Evaluation of automated pre-treatment and transit in-vivo do-simetry in radiotherapy using empirically determined parameters. Phys Imaging Radiat Oncol 16:113–129. https://doi.org/10.1016/j.phro.2020.09.011
doi: 10.1016/j.phro.2020.09.011
pubmed: 33458354
pmcid: 7807610
Esposito M, Piermattei A, Bresciani S, Orlandini LC, Falco MD, Giancaterino S et al (2021) Improving dose delivery accuracy with EPID in vivo dosimetry: results from a multicenter study. Strahlenther Onkol 197(7):633–643. https://doi.org/10.1007/s00066-021-01749-6
doi: 10.1007/s00066-021-01749-6
pubmed: 33594471
International Atomic Energy Agency (2013) Development of procedures for in vivo dosimetry in radiotherapy. IAEA, Vienna, Austria (IAEA Human Health Report No. 8)
Donaldson S (2008) Towards safer radiotherapy
MacDougall ND, Graveling M, Hansen VN, Brownsword K, Morgan A (2017) In vivo dosimetry in UK external beam radiotherapy: current and future usage. Br J Radiol 90(1072):20160915. https://doi.org/10.1259/bjr.20160915
doi: 10.1259/bjr.20160915
pubmed: 28205452
pmcid: 5605079
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B et al (2010) Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 37(8):4078–4101
doi: 10.1118/1.3438081
pubmed: 20879569
Hanna GG, Murray L, Patel R, Jain S, Aitken KL, Franks KN et al (2018) UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol (R Coll Radiol) 30(1):5–14. https://doi.org/10.1016/j.clon.2017.09.007
doi: 10.1016/j.clon.2017.09.007
pubmed: 29033164
Esposito M, Bastiani P, Ghirelli A et al (2018) Characterization of EPID software for VMAT transit dosimetry. Australas Phys Eng Sci Med 41(4):1021–1027. https://doi.org/10.1007/s13246-018-0693-0
doi: 10.1007/s13246-018-0693-0
pubmed: 30341673
Esposito M, Marrazzo L, Vanzi E, Russo S, Pallotta S, Talamonti C (2021) A validation method for EPID in vivo dosimetry algorithms. Appl Sci 11(22):10715
doi: 10.3390/app112210715
Esposito M, Ghirelli A, Pini S, Alpi P, Barca R, Fondelli S et al (2021) Clinical implementation of 3D in vivo dosimetry for abdominal and pelvic stereotactic treatments. Radiother Oncol 154:14–20. https://doi.org/10.1016/j.radonc.2020.09.011
doi: 10.1016/j.radonc.2020.09.011
pubmed: 32926910
Baehr A, Hummel D, Gauer T et al (2022) Risk management patterns in radiation oncology—results of a national survey within the framework of the patient safety in German radiation oncology (PaSaGeRO) project. Strahlenther Onkol. https://doi.org/10.1007/s00066-022-01984-5
doi: 10.1007/s00066-022-01984-5
pubmed: 35931889
pmcid: 10033570
Huq MS, Fraass BA, Dunscombe PB, Gibbons JP Jr, Ibbott GS, Mundt AJ et al (2016) The report of task group 100 of the AAPM: application of risk analysis methods to radiation therapy quality management. Med Phys 43(7):4209. https://doi.org/10.1118/1.4947547
doi: 10.1118/1.4947547
pubmed: 27370140
pmcid: 4985013
Schmitt D, Blanck O, Gauer T, Fix MK, Brunner TB, Fleckenstein J, Loutfi-Krauss B et al (2020) Technological quality requirements for stereotactic radiotherapy : expert review group consensus from the DGMP working group for physics and technology in stereotactic radiotherapy. Strahlenther Onkol 196(5):421–443. https://doi.org/10.1007/s00066-020-01583-2
doi: 10.1007/s00066-020-01583-2
pubmed: 32211939
pmcid: 7182540
Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C et al (2017) ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 124(1):11–17. https://doi.org/10.1016/j.radonc.2017.05.012
doi: 10.1016/j.radonc.2017.05.012
pubmed: 28687397
Moustakis C, Blanck O, Ebrahimi Tazehmahalleh F, Ka Heng Chan M, Ernst I, Krieger T, Duma MN et al (2017) Planning benchmark study for SBRT of early stage NSCLC : results of the DEGRO working group stereotactic radiotherapy. Strahlenther Onkol 193(10):780–790. https://doi.org/10.1007/s00066-017-1151-8
doi: 10.1007/s00066-017-1151-8
pubmed: 28567503
Giglioli FR, Strigari L, Ragona R et al (2016) Lung stereotactic ablative body radiotherapy: a large scale multi-institutional planning comparison for interpreting results of multi-institutional studies. Phys Med 32(4):600–606
doi: 10.1016/j.ejmp.2016.03.015
pubmed: 27061871
Esposito M, Maggi G, Marino C et al (2016) Multicentre treatment planning inter-comparison in a national context: the liver stereotactic ablative radiotherapy case. Phys Med 32(1):277–283
doi: 10.1016/j.ejmp.2015.09.009
pubmed: 26498378
Esposito M, Masi L, Zani M et al (2018) SBRT planning for spinal metastasis: indications from a large multicentric study. Strahlenther Onkol 195(3):226–235
doi: 10.1007/s00066-018-1383-2
pubmed: 30353349
McCowan PM, Asuni G, Van Uytven E et al (2017) Clinical implementation of a model-based in vivo dose verification system for stereotactic body radiation therapy—volumetric modulated arc therapy treatments using the electronic portal imaging device. Int J Radiat Oncol Biol Phys 97(5):1077–1084
doi: 10.1016/j.ijrobp.2017.01.227
pubmed: 28332992
McCurdy BMC, McCowan PM (2017) In vivo dosimetry for lung radiotherapy including SBRT. Phys Med 44:123–130. https://doi.org/10.1016/j.ejmp.2017.05.065
doi: 10.1016/j.ejmp.2017.05.065
pubmed: 28576581
Cilla S, Ianiro A, Craus M et al (2019) Epid-based in vivo dose verification for lung stereotactic treatments delivered with multiple breath-hold segmented volumetric modulated arc therapy. J Appl Clin Med Phys 20(3):37–44
doi: 10.1002/acm2.12538
pubmed: 30790439
pmcid: 6414179